| Literature DB >> 28353200 |
Kazuyuki Suzuki1,2,3, Ichiro Kumagai4, Yuichi Yoshida5, Akio Miyasaka5, Yasuhiro Takikawa5, Ryoichi Kamiya4, Kouryo Kondo4, Akinobu Kato4, Toshimi Chiba6, Hiroaki Okamoto7.
Abstract
We present a 60-year-old female patient with asymptomatic acute hepatitis E that was fortuitously detected during the course of ulcerative colitis (UC). She was admitted to hospital on October 30, 2015. Endoscopy and histological examination of the colon showed typical findings of UC. All parameters of liver function tests were normal on this date. Combination therapy with oral prednisolone and mesalazine was started and intravenous administration of infliximab once every 8 weeks was added later. Her symptoms gradually improved after these treatments, and she was discharged on February 7, 2016. In a periodic check-up on July 7, 2016, high levels of serum transaminases were detected in liver function tests. Although drug-induced liver injury was first suspected, anti-hepatitis E virus (HEV) immunoglobulin A was positive. The genotype and subgenotype of this HEV are 3 and 3a, respectively, although the infectious route of the HEV was unclear. Within 2 weeks after the onset of acute liver injury, the HEV viremia disappeared and her liver function tests improved. Examination of serum anti-HEV immunoglobulin A should be added at the time of abnormal liver function tests in patients with UC receiving immunosuppressive and biological drugs.Entities:
Keywords: Acute hepatitis E; Biological drug; Immunosuppressive drug; Opportunistic infection; Ulcerative colitis
Mesh:
Substances:
Year: 2017 PMID: 28353200 DOI: 10.1007/s12328-017-0730-7
Source DB: PubMed Journal: Clin J Gastroenterol ISSN: 1865-7265